Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Certificate of Analysis is batch-numbered and matched to the vial you receive
Dosing is determined by the concentration you achieved during reconstitution
Brain Activation Studies Neuroanatomical studies using c-Fos immunoreactivity (a marker of neuronal activation) mapped PT-141s central effects: Activation concentrated in hypothalamic nuclei including mPOA, paraventricular nucleus, and arcuate nucleus Limbic system activation in regions processing reward and motivation Dose-dependent activation patterns correlating with behavioral responses Selective activation in regions known to control sexual function across species Clinical Translation Gap: Despite robust preclinical evidence and successful Phase 3 trials in women, PT-141 currently has FDA approval only for premenopausal women with HSDD
The first is 17 mg/mL tirzepatide with 2 mg/mL niacinamide in a 4 mL vial
N-acetyl cysteine (NAC) is a popular precursor that the body converts into glutathione
